Grifols increases access to plasma-derived therapies as part of its commitment to donors and patients

- For the month of October, Grifols supports International Plasma Awareness Week (IPAW), an initiative organized by the Plasma Protein Therapeutics Association (PPTA) to raise global plasma awareness and the vital role of donors.

- In September, Grifols announced it entered into an agreement to acquire Tiancheng (Germany) Pharmaceutical Holdings for EUR 1,100 million, the largest owner of Biotest AG. An alliance that will boost the availability of plasma-derived medicines and increase access for patients.

- Grifols welcomes the promising post-hoc analysis recently published by Biotest AG on the efficacy of trimodulin\(^1\) (IgM concentrate) in a relevant subgroup of severely ill COVID-19 patients.

- In recent quarters, Grifols has expanded and diversified its access to plasma, as well as reinforced its plasma-center leadership, with 350 plasma donation centers across the United States and Europe.

**Barcelona, October 13, 2021** – Grifols has led several actions in recent quarters to reinforce its commitment to donors and patients and increase access to plasma-derived therapies. This commitment is mirrored by raising our voice supporting the PPTA’s International Plasma Awareness Week (IPAW); the recent investment in Biotest AG to increase patients’ access to plasma therapies; and its ongoing efforts to widen and diversify its global network of plasma collection centers.

**Celebrating the International Plasma Awareness Week: A clear responsibility to donors and patients**

In light of plasma’s essential role in global health care, Grifols recognizes the vital role of plasma donors, whose commitment and generosity make plasma-derived therapies possible.

\(^1\) Further information available at: biotest.com
The company spearheads a range of donor activities in its countries of operation, with the aim of forging long-lasting ties with donors.

For the month of October, Grifols and the Plasma Protein Therapeutics Association (PPTA) have joined forces for International Plasma Awareness Week (IPAW), a global initiative to recognize the contribution of plasma donors and their role in improving patients' health and wellbeing. IPAW also aims to raise awareness of plasma-derived medicines and their use in treating life-threatening conditions.

**Grifols acquires the largest shareholder of Biotest AG to increase patients' access to plasma-derived medicines**

Grifols closed an agreement with Tiancheng International Investment Ltd in September to acquire 100% of its shares in Tiancheng Pharmaceutical Holdings AG, owner of 89.88% of Biotest’s ordinary shares and 1.08% of its preferred shares for EUR 1.1 billion. This transaction further underscores Grifols’ commitment to increase patients’ access to plasma-based medicines around the world.

Through this alliance, Biotest and Grifols both fulfill their overriding missions of promoting the global availability of plasma-derived therapies.

This acquisition will significantly reinforce Grifols' industry capabilities by enhancing its plasma-derived medicines access, pipeline and sales presence, and will provide access to new scientific and industrial capabilities.

In parallel, Grifols will expand and diversify its plasma sourcing by adding 26 European plasma centers to its network and bolstering its operations and revenues in the EMEA (Europe, the Middle East and Africa) region.

**Biotest AG identifies benefits of trimodulin in a relevant subgroup of hospitalized COVID-19 patients**

Less than one month after announcing the investment, Grifols welcomes Biotest’s recent and promising results: the analysis of the complete data set of ESsCOVID (Escape from severe COVID-19) trial revealed efficacy of trimodulin (IgM concentrate) in a relevant subgroup of severely ill COVID-19 patients.

The detailed post-hoc analyses revealed a notable benefit in a relevant subgroup of hospitalized patients with early systemic inflammation. In this subgroup of 96 COVID-19 patients, trimodulin markedly reduced the progression and mortality of patients compared to the placebo group.
Grifols’ expansion plasma centers: A competitive advantage

Today, more than ever, Grifols has a competitive advantage thanks to the execution of its comprehensive strategy aimed at building a global and diversified plasma-center network.

The company boasts a network of more than 350 plasma centers that deliver an unparalleled capacity to secure plasma. More than 50 centers are located in Europe, with plans to open 10 in Egypt by year-end. At the same time, Grifols’ alliances in China, through Shanghai RAAS, and Canada further diversify its plasma sourcing, while promoting the self-sufficiency of these countries.

Throughout 2020 and 2021, Grifols accelerated the execution of its plasma-supply expansion plan through the acquisition of several plasma-collection centers and establishment of various supply agreements. These transactions have allowed the company to enlarge its capacity by approximately 1.9 million additional liters of plasma per year.

In parallel, Grifols continues to optimize supply chain efficiencies through ongoing operational improvements and robust inventory management.

Investor contact:
Investor Relations and Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21

Media contacts:
Raquel Lumbreras
Raquel_lumbreras@duomocomunicacion.com
Borja Gómez
Borja_gomez@duomocomunicacion.com
Duomo Comunicación – Grifols Press Office
Tel. +34 91 311 92 89 - 91 311 92 90
+34 659 57 21 85 / +34 650 40 22 25

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a
comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

---

**LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.